MovDisordV3, PascalFrancis, Curation, bibRecord, 002312

Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations

Identifieur interne : 002312 ( PascalFrancis/Curation ); précédent : 002311; suivant : 002313

Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations

Auteurs : Carlo Colosimo [Italie] ; Pablo Martinez-Martin [Espagne] ; Giovanni Fabbrini [Italie] ; Robert A. Hauser [États-Unis] ; Marcelo Merello [Argentine] ; Janis Miyasaki [Canada] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Olivier Rascol [France] ; Glenn T. Stebbins [États-Unis] ; Anette Schrag [Royaume-Uni] ; Christopher G. Goetz [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0376250

Descripteurs français

Pascal (Inist)
- Dyskinésie, Maladie de Parkinson, Pathologie du système nerveux, Force, Recommandation, Validité, Fiabilité.
Wicri :
- topic : Recommandation.

English descriptors

KwdEn :
- Dyskinesia, Force, Nervous system diseases, Parkinson disease, Recommendation, Reliability, Validity.

Abstract

Drug-induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated "Recommended" if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. "Suggested" scales met two of the above criteria and those meeting one were "Listed." Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang-Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS-26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS-26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re-ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations`
A11	`01`	`1`		`@1 COLOSIMO (Carlo)`
A11	`02`	`1`		`@1 MARTINEZ-MARTIN (Pablo)`
A11	`03`	`1`		`@1 FABBRINI (Giovanni)`
A11	`04`	`1`		`@1 HAUSER (Robert A.)`
A11	`05`	`1`		`@1 MERELLO (Marcelo)`
A11	`06`	`1`		`@1 MIYASAKI (Janis)`
A11	`07`	`1`		`@1 POEWE (Werner)`
A11	`08`	`1`		`@1 SAMPAIO (Cristina)`
A11	`09`	`1`		`@1 RASCOL (Olivier)`
A11	`10`	`1`		`@1 STEBBINS (Glenn T.)`
A11	`11`	`1`		`@1 SCHRAG (Anette)`
A11	`12`	`1`		`@1 GOETZ (Christopher G.)`
A14	`01`			`@1 Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome @2 Rome @3 ITA @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health @2 Madrid @3 ESP @Z 2 aut.`
A14	`03`			`@1 Parkinson's Disease and Movement Disorders Center, University of South Florida @2 Tampa, Florida @3 USA @Z 4 aut.`
A14	`04`			`@1 Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI) @2 Buenos Aires @3 ARG @Z 5 aut.`
A14	`05`			`@1 The Movement Disorders Centre, University Health Network, University of Toronto @2 Toronto @3 CAN @Z 6 aut.`
A14	`06`			`@1 Department of Neurology, Innsbruck Medical University @2 Innsbruck @3 AUT @Z 7 aut.`
A14	`07`			`@1 Department of Pharmacology, Faculdade de Medicina de Lisboa @3 PRT @Z 8 aut.`
A14	`08`			`@1 Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University @2 Toulouse @3 FRA @Z 9 aut.`
A14	`09`			`@1 Department of Neurological Sciences, Rush University Medical Center @2 Chicago, Illinois @3 USA @Z 10 aut. @Z 12 aut.`
A14	`10`			`@1 Department of Clinical Neurosciences, Institute of Neurology, University College London @2 London @3 GBR @Z 11 aut.`
A20				`@1 1131-1142`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000191760240040`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 31 ref.`
A47	`01`	`1`		`@0 10-0376250`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Drug-induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated "Recommended" if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. "Suggested" scales met two of the above criteria and those meeting one were "Listed." Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang-Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS-26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS-26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re-ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Dyskinésie @5 01`
C03	`01`	`X`	`ENG`	`@0 Dyskinesia @5 01`
C03	`01`	`X`	`SPA`	`@0 Disquinesia @5 01`
C03	`02`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Force @5 09`
C03	`04`	`X`	`ENG`	`@0 Force @5 09`
C03	`04`	`X`	`SPA`	`@0 Fuerza @5 09`
C03	`05`	`X`	`FRE`	`@0 Recommandation @5 10`
C03	`05`	`X`	`ENG`	`@0 Recommendation @5 10`
C03	`05`	`X`	`SPA`	`@0 Recomendación @5 10`
C03	`06`	`X`	`FRE`	`@0 Validité @5 11`
C03	`06`	`X`	`ENG`	`@0 Validity @5 11`
C03	`06`	`X`	`SPA`	`@0 Validez @5 11`
C03	`07`	`X`	`FRE`	`@0 Fiabilité @5 12`
C03	`07`	`X`	`ENG`	`@0 Reliability @5 12`
C03	`07`	`X`	`SPA`	`@0 Fiabilidad @5 12`
C07	`01`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 37`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 37`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 37`
C07	`02`	`X`	`FRE`	`@0 Mouvement involontaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Involuntary movement @5 38`
C07	`02`	`X`	`SPA`	`@0 Movimiento involuntario @5 38`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 40`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 40`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 40`
C07	`04`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 41`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 41`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 41`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 42`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 42`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 42`
C07	`06`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 43`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 43`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 43`
N21				`@1 242`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A07

Links to Exploration step

Pascal:10-0376250

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>The Movement Disorders Centre, University Health Network, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0376250</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0376250 INIST</idno>
<idno type="RBID">Pascal:10-0376250</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A07</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002312</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations</title>
<author><name sortKey="Colosimo, Carlo" sort="Colosimo, Carlo" uniqKey="Colosimo C" first="Carlo" last="Colosimo">Carlo Colosimo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Martinez Martin, Pablo" sort="Martinez Martin, Pablo" uniqKey="Martinez Martin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Italie</country>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author><name sortKey="Miyasaki, Janis" sort="Miyasaki, Janis" uniqKey="Miyasaki J" first="Janis" last="Miyasaki">Janis Miyasaki</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>The Movement Disorders Centre, University Health Network, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Portugal</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Force</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Recommendation</term>
<term>Reliability</term>
<term>Validity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Force</term>
<term>Recommandation</term>
<term>Validité</term>
<term>Fiabilité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Recommandation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Drug-induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated "Recommended" if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. "Suggested" scales met two of the above criteria and those meeting one were "Listed." Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang-Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS-26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS-26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re-ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>COLOSIMO (Carlo)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MARTINEZ-MARTIN (Pablo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>FABBRINI (Giovanni)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MERELLO (Marcelo)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MIYASAKI (Janis)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>SAMPAIO (Cristina)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>STEBBINS (Glenn T.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SCHRAG (Anette)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GOETZ (Christopher G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences and Neuromed Institute, Sapienza University of Rome</s1>
<s2>Rome</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Area of Applied Epidemiology, National Center for Epidemiology and CIBERNED, Carlos III Institute of Health</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Parkinson's Disease and Movement Disorders Center, University of South Florida</s1>
<s2>Tampa, Florida</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Movement Disorders Section, Institute for Neurological Research Raul Carrea (FLENI)</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>The Movement Disorders Centre, University Health Network, University of Toronto</s1>
<s2>Toronto</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Pharmacology, Faculdade de Medicina de Lisboa</s1>
<s3>PRT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Laboratoire de Pharmacologie Médicale et Clinique, Toulouse University</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>10 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Department of Clinical Neurosciences, Institute of Neurology, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA20><s1>1131-1142</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000191760240040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>31 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0376250</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Drug-induced dyskinesia is a common phenomenon in Parkinson's disease (PD) and is often socially as well as physically disabling for patients. The Movement Disorders Society commissioned a task force to assess available clinical rating scales, critique their clinimetric properties, and make recommendations regarding their clinical utility. A task force composed six clinical researchers who systematically searched the literature for scales measuring dyskinesia in PD, evaluated the scales' previous use, performance parameters, and quality of validation data (if available). A scale was designated "Recommended" if the scale has been used in clinical studies beyond the group that developed it, has been specifically used in PD reports, and if clinimetric studies have established that it is a valid, reliable, and sensitive. "Suggested" scales met two of the above criteria and those meeting one were "Listed." Based on the systematic review, eight rating scales for dyskinesia that have either been validated or used in PD were identified. These were the Abnormal Involuntary Movement Scale (AIMS), The Unified Parkinson's Disease Rating Scale (UPDRS) part IV, the Obeso Dyskinesia Rating Scale, the Rush Dyskinesia Rating Scale, the Clinical Dyskinesia Rating Scale (CDRS), the Lang-Fahn Activities of Daily Living Dyskinesia Scale, the Parkinson Disease Dyskinesia Scale (PDYS-26), and the Unified Dyskinesia Rating Scale (UDysRS). Based on this review, at present two of the reviewed dyskinesia scales (AIMS and the Rush Dyskinesia Rating Scale) fulfill criteria for Recommended for use in PD populations, albeit weakly so; all of the remaining met criteria to be Suggested. However, the two most recent scales (PDYS-26 and UDysRS) have excellent clinimetric properties and appear to provide a reliable and valid assessment tool of dyskinesia in PD. If they are used successfully beyond the groups that developed them, both have the potential to be re-ranked as Recommended. As further testing of these scales in PD is warranted, no new scales are needed until the available scales are fully tested clinimetrically.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Force</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Force</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Fuerza</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Recommandation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Recommendation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Recomendación</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Validité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Validity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Validez</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Fiabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Reliability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Fiabilidad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>43</s5>
</fC07>
<fN21><s1>242</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002312 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002312 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0376250
   |texte=   Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations

Task Force Report on Scales to Assess Dyskinesia in Parkinson's Disease: Critique and Recommendations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri